Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mathew John Joseph"'
Autor:
F. Anthony Greco, Dana S. Thompson, Howard A. Burris, John D. Hainsworth, David R. Spigel, Dianna Shipley, Mathew John Joseph, M. Kelly Hagan
Publikováno v:
Cancer. 124:1982-1991
Background The best treatment for patients with advanced non-small cell lung cancer (NSCLC) and a poor performance status is not well defined. In this phase 2 trial, patients were randomized to receive treatment with either single-agent pemetrexed or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88a220da5f26eea4cb36d9cfb002ad0f
https://doi.org/10.1002/cncr.30986
https://doi.org/10.1002/cncr.30986
Autor:
Rami Owera, Howard A. Burris, Mathew John Joseph, Ruth E. Lamar, David R. Spigel, Johanna C. Bendell, Cassie M. Lane, D. S. Thompson, Chris Earwood, William Penley, Todd M. Bauer
Publikováno v:
Cancer Investigation. 34:265-270
AUY922 is an inhibitor of heat shock protein 90 (Hsp90). Hsp90 inhibitors induce kit degradation in preclinical gastrointestinal stromal tumor (GIST) models. This trial was designed to determine the progression-free survival (PFS) of patients with GI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a09afdb1c50d9eff792e7466b133bfb
https://doi.org/10.1080/07357907.2016.1193746
https://doi.org/10.1080/07357907.2016.1193746
Autor:
Michel E. Kuzur, Dianna Shipley, Mathew John Joseph, Laura Blakely, Cassie M. Lane, Mark Mainwaring, Chris Earwood, Johanna C. Bendell, Chandra Reddy, Ronald Blachly, Kirk Barnes
Publikováno v:
Cancer investigation. 35(6)
This phase-2 trial evaluated the efficacy of axitinib as maintenance therapy for patients with metastatic colorectal cancer (mCRC) following first-line treatment with FOLFOX/bevacizumab. Patients with mCRC received mFOLFOX/bevacizumab followed by axi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::692c20fb281726eabcbbe4498488e614
https://pubmed.ncbi.nlm.nih.gov/28426267
https://pubmed.ncbi.nlm.nih.gov/28426267
Autor:
Natalie R. Dickson, Janet A Matheny, Jeffrey Patton, Mathew John Joseph, Larry Edward Bilbrey, Stacey L Poole
Publikováno v:
Journal of Clinical Oncology. 37:278-278
278 Background: A rural oncology/hematology clinic located a far distance from the local community hospital was not able to provide hospital consultation support. Collaboration between the practice and the hospital resulted in a telemedicine pilot st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92d0e371c8654c00cc8ca8e43f3ec6d3
https://doi.org/10.1200/jco.2019.37.27_suppl.278
https://doi.org/10.1200/jco.2019.37.27_suppl.278
Publikováno v:
Journal of Clinical Oncology. 33:e14673-e14673
e14673 Background: Maintenance therapy is commonly used in the first-line treatment of mCRC. Maintenance therapy options include fluorouracil plus bev and bev single agent. Ax is an oral, potent, a...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b5dc9db189d6f1c940c961d4532af02
https://doi.org/10.1200/jco.2015.33.15_suppl.e14673
https://doi.org/10.1200/jco.2015.33.15_suppl.e14673
Autor:
John D. Hainsworth, David R. Spigel, James D. Peyton, Mathew John Joseph, Sang Y. Huh, Edward K. Barnes, David Michael Waterhouse, Raven Quinn, Victor G. Gian, Davey B. Daniel, F. A. Greco, Howard A. Burris, Christopher F. Lobo
Publikováno v:
Journal of Clinical Oncology. 30:7035-7035
7035 Background: Adjuvant chemotherapy improves overall survival (OS) in patients (pts) with resected non small cell lung cancer (NSCLC). Bevacizumab and erlotinib improve survival in pts with advanced unresectable NSCLC. This randomized phase II mul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b5bd6408288e58d2ec8bc4850b3478c
https://doi.org/10.1200/jco.2012.30.15_suppl.7035
https://doi.org/10.1200/jco.2012.30.15_suppl.7035